

# Sam Hollingworth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4897828/publications.pdf>

Version: 2024-02-01

123  
papers

2,029  
citations

279798

23  
h-index

302126

39  
g-index

126  
all docs

126  
docs citations

126  
times ranked

3050  
citing authors

#	ARTICLE	IF	CITATIONS
1	International trends in clozapine use: a study in 17 countries. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 37-51.	4.5	188
2	Marked increase in proton pump inhibitors use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1019-1024.	1.9	101
3	The impact of clozapine on hospital use: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 296-309.	4.5	90
4	Patterns of Antipsychotic Medication Use in Australia 2002-2007. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 372-377.	2.3	83
5	Anxiolytic, hypnotic and sedative medication use in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 280-288.	1.9	74
6	Affective and anxiety disorders: prevalence, treatment and antidepressant medication use. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 513-9.	2.3	62
7	Changing patterns of antiepileptic drug use in pregnant Australian women. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 89-93.	2.1	59
8	Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose. <i>CNS Drugs</i> , 2018, 32, 101-116.	5.9	50
9	Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: <scp>A</scp> randomized controlled trial (<scp>CODEX</scp>). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1050-1055.	4.4	49
10	Antiepileptic drugs in Australia: 2002-2007. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 82-89.	1.9	46
11	Prescribing patterns of dental practitioners in Australia from 2001 to 2012. <i>Antimicrobials. Australian Dental Journal</i> , 2017, 62, 52-57.	1.5	38
12	Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1149-1160.	2.4	38
13	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. <i>Journal of Psychopharmacology</i> , 2016, 30, 227-236.	4.0	37
14	Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep. <i>Endocrinology</i> , 1996, 137, 2424-2431.	2.8	34
15	Opioid analgesic prescribing in Australia: a focus on gender and age. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 628-636.	1.9	34
16	Sociodemographic correlates of antidepressant utilisation in Australia. <i>Medical Journal of Australia</i> , 2009, 190, 479-483.	1.7	33
17	Australian National Trends in Stimulant Dispensing: 2002-2009. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 332-336.	2.3	32
18	The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. <i>Menopause</i> , 2018, 25, 109-120.	2.0	32

#	ARTICLE	IF	CITATIONS
19	Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms.. Endocrinology, 1995, 136, 1233-1240.	2.8	31
20	Effect of Late Hypothalamo-Pituitary Disconnection on the Development of the HPA Axis in the Ovine Fetus and the Initiation of Parturition. Journal of Neuroendocrinology, 1994, 6, 25-31.	2.6	29
21	Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013. Pharmacopsychiatry, 2015, 48, 164-169.	3.3	29
22	The trigger for parturition in sheep: fetal hypothalamus or placenta?. Journal of Developmental Physiology, 1991, 15, 71-9.	0.3	27
23	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2021, 47, 948-958.	4.3	26
24	Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. Pharmacy (Basel,) 2020, 10, 265-270.	1.6	26
25	Prescribing patterns of analgesics and other medicines by dental practitioners in Australia from 2001 to 2012. Community Dentistry and Oral Epidemiology, 2017, 45, 303-309.	1.9	25
26	The prescribing of antiepileptic drugs for pregnant Australian women. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 49-53.	1.0	24
27	Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care, 2019, 42, 69-76.	8.6	24
28	Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Australian and New Zealand Journal of Public Health, 2013, 37, 132-138.	1.8	23
29	Consumer knowledge and perceptions about antibiotics and upper respiratory tract infections in a community pharmacy. International Journal of Clinical Pharmacy, 2015, 37, 1213-1221.	2.1	23
30	Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study. International Journal of Drug Policy, 2019, 69, 46-52.	3.3	23
31	Opioid analgesic use in Australia and The Netherlands: a cross-country comparison. International Journal of Clinical Pharmacy, 2017, 39, 874-880.	2.1	21
32	Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. International Journal of Technology Assessment in Health Care, 2020, 36, 8-11.	0.5	21
33	Understanding quality use of medicines in refugee communities in Australian primary care: a qualitative study. British Journal of General Practice, 2016, 66, e397-e409.	1.4	20
34	Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders' capacity, needs, policy areas of demand and perspectives in Nigeria. Globalization and Health, 2020, 16, 58.	4.9	20
35	Clozapine-induced myocarditis: Separating the wheat from the chaff. Australian and New Zealand Journal of Psychiatry, 2015, 49, 188-188.	2.3	19
36	Antidepressant use in Australia and Sweden: A cross-country comparison. Pharmacoepidemiology and Drug Safety, 2021, 30, 409-417.	1.9	19

#	ARTICLE	IF	CITATIONS
37	Using Prescription and Wastewater Data to Estimate the Correction Factors of Atenolol, Carbamazepine, and Naproxen for Wastewater-Based Epidemiology Applications. <i>Environmental Science &amp; Technology</i> , 2021, 55, 7551-7560.	10.0	19
38	Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993â€“2014. <i>Psychopharmacology</i> , 2018, 235, 1915-1921.	3.1	17
39	In Australia are people born in other countries at higher risk of road trauma than locally born people?. <i>Accident Analysis and Prevention</i> , 2004, 36, 375-381.	5.7	16
40	Utilization of antiâ€“Parkinson drugs in Australia: 1995â€“2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 450-456.	1.9	16
41	Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 39.	1.5	16
42	Dental opioid prescribing rates after the up-scheduling of codeine in Australia. <i>Scientific Reports</i> , 2020, 10, 8463.	3.3	15
43	Prostaglandin G/H synthase activity in ovine cotyledons: a gestational profile. <i>Eicosanoids</i> , 1990, 3, 231-6.	0.7	15
44	A new model of integrated primary-secondary care for complex diabetes in the community: study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 382.	1.6	14
45	Case conference primary-secondary care planning at end of life can reduce the cost of hospitalisations. <i>BMC Palliative Care</i> , 2016, 15, 84.	1.8	14
46	Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 259-265.	3.6	14
47	Prescribing trends in cognition enhancing drugs in Australia. <i>International Psychogeriatrics</i> , 2011, 23, 238-245.	1.0	13
48	How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1014-1020.	3.0	13
49	Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. <i>BJPsych Open</i> , 2015, 1, 67-73.	0.7	12
50	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , 2017, 35, 40-46.	2.5	12
51	Secondary Prevention of Osteoporosis in Australia. <i>Drugs and Aging</i> , 2010, 27, 255-264.	2.7	11
52	Psychiatric Drug Prescribing in Elderly Australians: Time for Action. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 705-708.	2.3	11
53	Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?. <i>International Journal of Infectious Diseases</i> , 2019, 89, 137-145.	3.3	11
54	Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal. <i>Inquiry (United States)</i> , 2019, 56, 004695801988757.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 655-659.	3.0	10
56	Duration of opioid use and association with socioeconomic status, daily dose and formulation: a two-decade population study in Queensland, Australia. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 340-350.	2.1	10
57	Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1712-1716.	3.0	9
58	Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations. <i>Primary Care Diabetes</i> , 2017, 11, 344-347.	1.8	9
59	Multiple opioid prescribers: A genuine quest for treatment rather than aberrant behaviour. A two-decade population-based study. <i>Addictive Behaviors</i> , 2020, 108, 106458.	3.0	9
60	What do we need to know? Data sources to support evidence-based decisions using health technology assessment in Ghana. <i>Health Research Policy and Systems</i> , 2020, 18, 41.	2.8	9
61	National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. <i>Australasian Psychiatry</i> , 2013, 21, 442-445.	0.7	8
62	Effects of decentralisation and health system reform on health workforce and quality of care in Indonesia, 1993-2007. <i>International Journal of Health Planning and Management</i> , 2015, 30, E16-30.	1.7	8
63	Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit. <i>Drug Safety</i> , 2018, 41, 1023-1033.	3.2	8
64	Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia. <i>Climacteric</i> , 2019, 22, 489-497.	2.4	8
65	Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 547-555.	1.9	8
66	Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms. <i>Endocrinology</i> , 1995, 136, 1233-1240.	2.8	8
67	Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders. <i>F1000Research</i> , 2020, 9, 364.	1.6	8
68	Community-based integrated care versus hospital outpatient care for managing patients with complex type 2 diabetes: costing analysis. <i>Australian Health Review</i> , 2021, 45, 42.	1.1	7
69	Quality of physical resources of health facilities in Indonesia: a panel study 1993-2007. <i>International Journal for Quality in Health Care</i> , 2013, 25, 488-496.	1.8	6
70	Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. <i>Drugs - Real World Outcomes</i> , 2015, 2, 199-203.	1.6	6
71	Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, LC01-LC05.	0.8	6
72	Bortezomib use and outcomes for the treatment of multiple myeloma. <i>Internal Medicine Journal</i> , 2020, 50, 1059-1066.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Pharmaceutical opioids utilisation by dose, formulation, and socioeconomic status in Queensland, Australia: a population study over 22 years. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 328-339.	2.1	6
74	Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre. <i>BMC Women's Health</i> , 2021, 21, 348.	2.0	6
75	Rebound increase in fetal breathing movements after 24-h prostaglandin E2 infusion in fetal sheep. <i>Journal of Applied Physiology</i> , 1996, 80, 166-175.	2.5	5
76	Multiple sclerosis disease modifying medicine utilisation in Australia. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2083-2087.	1.5	5
77	Repeat prescriptions and antibiotic resistance: findings from Australian community pharmacy. <i>International Journal of Pharmacy Practice</i> , 2017, 25, 50-58.	0.6	5
78	Medicine use during acute and chronic postinjury periods in whiplash-injured individuals. <i>Pain</i> , 2019, 160, 844-851.	4.2	5
79	Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102835.	2.0	5
80	Chronic administration of low doses of adrenocorticotropin to hypophysectomized fetal sheep leads to normal term labor. <i>Endocrinology</i> , 1994, 134, 1389-1394.	2.8	5
81	Clozapine in the community: Improved access or risky free-for-all?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 863-865.	2.3	4
82	Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e253-e261.	1.1	4
83	A Review of Medication Use as an Indicator of Human Health Impact in Environmentally Stressed Areas. <i>Annals of Global Health</i> , 2018, 82, 111.	2.0	4
84	Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 440-447.	3.0	4
85	Research governance authorisation: the next frontier. <i>Australian Health Review</i> , 2021, 45, 389-392.	1.1	4
86	Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110006.	2.7	4
87	Trends in Australian dental prescribing of antibiotics: 2005-2016. <i>Australian Dental Journal</i> , 2021, 66 Suppl 1, S37-S41.	1.5	4
88	Clozapine use and prevalence in Australia 2016-2020. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 305-306.	2.3	4
89	Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep. <i>Endocrinology</i> , 1996, 137, 2424-2431.	2.8	4
90	Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 836-843.	2.1	4

#	ARTICLE	IF	CITATIONS
91	Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 907-912.	0.8	4
92	Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211049.	2.7	4
93	Triptan use in Australia 1997-2015: A pharmacoepidemiological study. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 155-159.	2.1	3
94	Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center. <i>BMC Rheumatology</i> , 2020, 4, 27.	1.6	3
95	Bazett's correction formula overestimates the corrected QT among patients with antipsychotic induced tachycardia. <i>Schizophrenia Research</i> , 2021, 231, 22-23.	2.0	3
96	Opioid medication prescribing in Queensland, 1997-2018: a population study. <i>Medical Journal of Australia</i> , 2021, 215, 137-138.	1.7	3
97	Antibiotic use in Australian and Swedish primary care: a cross-country comparison. <i>Scandinavian Journal of Primary Health Care</i> , 2022, 40, 95-103.	1.5	3
98	The impact of COVID-19 on antidepressant sales and prescription dispensing in Australia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 871-872.	2.3	3
99	Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. <i>Journal of the Medical Library Association: JMLA</i> , 2022, 110, 185-204.	1.7	3
100	Shift in disease burden from communicable to non-communicable diseases: aiming to achieve Universal Health Coverage in Nepal. <i>Perspectives in Public Health</i> , 2015, 135, 177-178.	1.6	2
101	Off-label use of tumour necrosis factor- $\alpha$ inhibitors and anakinra at an Australian tertiary hospital. <i>Internal Medicine Journal</i> , 2016, 46, 1386-1391.	0.8	2
102	Forecasting the amount and cost of medicine to treat type 2 diabetes mellitus in Nepal using knowledge on medicine usage from a developed country. <i>Journal of Pharmaceutical Health Services Research</i> , 2019, 10, 91-99.	0.6	2
103	Trends in Systemic Antifungal Use in Australia, 2005-2016: a Time-Series Analysis. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 254-261.	1.2	2
104	Forecasting the quantity and cost of medicines to treat non-communicable diseases in low- and middle-income countries: Applying knowledge on medicine use from developed countries. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 257-258.	3.0	1
105	Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study. <i>Journal of Traditional Chinese Medical Sciences</i> , 2018, 5, 100-109.	0.2	1
106	Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib. <i>Anti-Cancer Drugs</i> , 2018, 29, 786-790.	1.4	1
107	ICU Patients' Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 586893.	3.5	1
108	Patient concerns regarding antidepressant drug-drug interactions: a retrospective analysis using data from a medicines call centre. <i>Journal of Primary Health Care</i> , 2022, , .	0.6	1

#	ARTICLE	IF	CITATIONS
109	Parity in female authorship in Australian pharmacoepidemiology research leveraging medicine dispensing data: How well are we doing?. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 1010-1012.	1.9	1
110	The metabolism and excretion of oestradiol-3 <sup>12</sup> -d-glucuronide in rats. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1988, 90, 99-101.	0.2	0
111	PHP34 THE EVALUATION OF HEALTH-CARE SYSTEMS OF CHINA, HONG KONG, VIETNAM, THAILAND, MALAYSIA, SINGAPORE AND AUSTRALIA. <i>Value in Health</i> , 2010, 13, A538.	0.3	0
112	Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew460.	1.9	0
113	Knowledge and attitudes of final year pharmacy students toward opioid substitution therapy. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 216-221.	0.8	0
114	Patterns in use and costs of subsidising 5-aminosalicylic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. <i>Digestive and Liver Disease</i> , 2018, 50, 314-317.	0.9	0
115	More needs to be spent on hepatitis C treatment, not less. <i>Internal Medicine Journal</i> , 2018, 48, 364-366.	0.8	0
116	Response to Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. <i>Diabetes Care</i> 2019;42:69â€“76. <i>Diabetes Care</i> , 2019, 42, e79-e80.	8.6	0
117	Withdrawal and Misuse Concerns of Consumers regarding Opioid Analgesic and Anxiolytic, Hypnotic and Sedative Medicines. <i>Substance Use and Misuse</i> , 2020, 55, 1980-1992.	1.4	0
118	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A realâ€“world study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1371-1379.	1.9	0
119	Questioning the Accuracy and Interpretation of Dispensed Patterns of Dental Emergency Medicines. <i>International Dental Journal</i> , 2021, 71, 281-282.	2.6	0
120	Harnessing medicines data at low cost to deliver better and safer care. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1621-1623.	1.9	0
121	Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin. <i>Australian Health Review</i> , 2021, 45, 261.	1.1	0
122	Cost saving with a GP-led integrated health service delivery model for complex chronic disease: an optimal Beacon practice. <i>International Journal of Integrated Care</i> , 2018, 18, 25.	0.2	0
123	Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders. <i>F1000Research</i> , 0, 9, 364.	1.6	0